Comparative Pharmacology
Head-to-head clinical analysis: POLOCAINE versus ROPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLOCAINE versus ROPIVACAINE HYDROCHLORIDE.
POLOCAINE vs ROPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting the influx of sodium ions, thereby blocking nerve impulse propagation.
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
100 mg orally every 12 hours
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2.0 hours in adults; prolonged to 3-5 hours in hepatic impairment and neonates.
Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance.
Hepatic metabolism to 2,6-xylidine and 4-hydroxy-2,6-xylidine; <10% excreted unchanged in urine; approximately 70-80% of metabolites excreted renally, with <5% in feces.
Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor.
Category C
Category A/B
Local Anesthetic
Local Anesthetic